BioSpace News Archive

Immatics N.V. announced that its IMA203 TCR-T program has received Regenerative Medicine Advanced Therapy designation from the FDA Center for Biologics Evaluation and Research in multiple relapsed and/or refractory HLA-A*02:01-positive and PRAME-expressing cancers, including cutaneous melanoma, uveal melanoma, endometrial carcinoma, synovial sarcoma, and ovarian cancer.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the European Society of Gene & Cell Therapy has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium.

Spago Nanomedical AB announces the publication of four new patent applications filed with the European Patent Office to expand and extend the patent protection for the company’s radionuclide therapy Tumorad.

Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent in SEK and 42 percent in local currencies. • Organic growth accounted for 37 percent and acquired growth for 5 percent.

Genascence Corporation announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis demonstrated that it was safe and well tolerated.

ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia.

Life Molecular Imaging and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® has received regulatory approval from National Medical Products Administration in China.

SOPHiA GENETICS SA, a cloud-native software company and a leader in data-driven medicine, announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023.

Science 37 Holdings, Inc., the industry-leading Metasite™ announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023.

Vektor Medical, a pioneer in arrhythmia care and developer of vMap®, the world’s first technology to accurately map arrhythmias using the patient’s 12-lead ECG data, announces the American Medical Association CPT Editorial Panel has approved a new Category III CPT code for the use of vMap’s noninvasive arrhythmia analysis.